Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Codex DNA, Inc. (DNAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.89+0.06 (+0.61%)
At close: 4:00PM EDT
9.89 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.83
Open9.80
Bid9.75 x 1000
Ask11.00 x 1100
Day's Range9.79 - 10.23
52 Week Range9.53 - 25.70
Volume44,964
Avg. Volume112,021
Market Cap279.184M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
  • Motley Fool

    Codex DNA, Inc. (DNAY) Q2 2021 Earnings Call Transcript

    This afternoon, Codex DNA released its financial results for the second quarter ended June 30, 2021. Joining me today from Codex DNA, are Todd Nelson, our chief executive officer, and Dan Gibson, our chief technology officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws.

  • GlobeNewswire

    Codex DNA Reports Second Quarter 2021 Financial Results

    SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. “During the second quarter, Codex DNA took a big step forward in the evolution of our business. We successfully closed an IPO, strengthened the diversity of our leadership team and Board of Directors, enabled new downstream mRNA applications, expanded our customer base, and grew revenue

  • GlobeNewswire

    Codex DNA Announces Synthetic Biology Collaboration with U.S. Department of Agriculture to Combat Citrus Greening Disease

    Codex DNA to contribute novel synthetic biology-based solutions to stop the spread of a global disease that continues to devastate the citrus industrySAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a collaboration with researchers from the U.S. Department of Agriculture’s (USDA) Agricultural Research Service (ARS), Cornell University, the University of Florida, the University of California at

Advertisement
Advertisement